Vertex Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 2
- Active events
- 3
- Connections
- 194
What's happening
Active this week
-
Multiple financial firms, including Americana Partners and Summit Global Investments, adjusted their holdings in Vertex Pharmaceuticals on November 4, 2026.Some support1 report
-
Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.Some support6 reports
-
Vertex Pharmaceuticals added PALSONIFY as its fourth pillar in a recent acquisition.Some support1 report
Earlier this month
-
CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Some support3 reports
-
Sumitomo Mitsui Trust Holdings and Daiwa Securities Group announced changes to their holdings and ratings for Vertex Pharmaceuticals stock.Some support1 report
-
Mirae Asset Global Investments Co. Ltd. purchased shares of Vertex Pharmaceuticals.Some support1 report
-
CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.Well supported7 reports1 development inside
-
Financial firms, including RBC, TD Cowen, Leerink Partners, and Morgan Stanley, raised price targets and provided coverage for Vertex Pharmaceuticals.Some support1 report
-
NIH funded pivotal research for drug development involving Vertex Pharmaceuticals.Some support2 reports
One to three months ago
-
The competitive landscape is shifting as Amazon's Leo challenges Starlink's business, while Vertex Pharmaceuticals demonstrates market dominance over SpaceX.Well supported3 reports
-
Both Vertex Pharmaceuticals and The Pennant Group operate within the healthcare sector.Some support1 report
-
Vertex Pharmaceuticals CEO leads the company's strategic business direction.Some support1 report
-
Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.Some support2 reports
-
Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.Some support1 report
-
Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.Some support1 report
-
Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.Some support1 report
-
Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.Some support1 report
-
Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.Some support1 report
-
AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).Some support1 report
-
Norges Bank acquired a new position in the shares of Vertex Pharmaceuticals.Some support2 reports
-
Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.Some support1 report
-
Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.Some support2 reports1 development inside
-
Siona's trial failure allowed Vertex dominance to surge.Some support2 reports
Gone quiet
No new reports in 90+ days-
FogPharma and Vertex Pharmaceuticals are involved in drug development.Some support1 report
-
Vertex Pharmaceuticals filed documents with the SEC detailing institutional investment oversight.Some support1 report
-
Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.Some support2 reports
-
Ono Pharmaceutical and Vertex Pharmaceuticals signed an exclusive collaboration for Povetacicept in Japan and South Korea.Some support3 reports
-
Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.Some support5 reports
-
MarketBeat listed Vertex, Alnylam, Regeneron, Amgen, Danaher, TG Therapeutics, and Gilead Sciences as stocks to watch.Some support4 reports
-
Vertex Pharmaceuticals and Entera Bio were compared based on their market metrics.Some support1 report
-
Leerink Partners advised Crinetics during the acquisition process, while analyst commentary scrutinized the acquisition premium.Some support1 report
-
Various ETFs, including Invesco and VanEck, are reported to hold significant positions in major biotech and pharmaceutical companies.Some support5 reports1 development inside
-
Moderna and Vertex Pharmaceuticals are now holdings in the GNOM ETF.Some support1 report
-
Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.Well supported11 reports
-
The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.Well supported10 reports
-
Market activity on July 7, 2026 includes Deutsche Bank upgrading First Solar stock, the acquisition of Crinetics by Vertex Pharmaceuticals, and market selloffs affecting chip stocks and Korea.Some support2 reports
-
Vertex Pharmaceuticals stock gains far exceeded S&P 500 returns on July 6, 2026.Some support1 report
-
CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.Well supported18 reports
-
MarketBeat featured Danaher, Moderna, and Vertex Pharmaceuticals in its stock screener.Well supported25 reports
-
Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.Some support3 reports1 development inside
-
Vertex Pharmaceuticals stock price objective was boosted, triggering a requirement for 13F filings regarding stock ownership.Some support1 report1 development inside
-
Carmen Bozic, CMO of Vertex Pharmaceuticals, sold company stock on June 23, 2026.Some support1 report
-
CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.Some support1 report
-
Benzinga reported on the financial performance of Vertex Pharmaceuticals.Some support1 report
-
Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.Some support1 report
-
The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.Some support1 report
-
EPAM Systems, Paramount Global, and Vertex Pharmaceuticals were identified as major high-growth stocks.Speculative1 report
-
Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.Some support1 report
-
Vertex Pharmaceuticals presented clinical data at the American Diabetes Association conference held in Chicago on June 25, 2025.Speculative2 reports
-
PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.Speculative2 reports
-
Vertex Pharmaceuticals' performance is linked to broader market movements, supported by new reimbursement agreements in Ireland and Denmark.Speculative2 reports
-
A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.Well supported4 reports
-
Vertex Pharmaceuticals and Inspire Medical Systems both reported positive Earnings Stock Purchase Plan (ESP) figures.Some support1 report
-
Vertex Pharmaceuticals, based in Boston, launched JOURNAVX, a new medication offering a safer alternative to opioids.Some support1 report
-
FDA approved Journavx for pain treatment on August 1, 2025.Some support2 reports
-
Vertex Pharmaceuticals was removed from Russell indexes on August 7, 2025.Some support1 report
-
Buying opportunities emerged for Costco, Netflix, ASML Holding, and Vertex Pharmaceuticals following a market pullback on August 8, 2025.Some support1 report1 development inside
-
The Buffett Indicator reached a record high, involving Vertex Pharmaceuticals.Some support1 report
-
FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Vertex Pharmaceuticals
Events traced to Vertex Pharmaceuticals, step by step, newest firstAround Vertex Pharmaceuticals this week
News at the entities that move Vertex Pharmaceuticals most-
CRISPR Therapeutics StructuralCRISPR Therapeutics presented clinical data at the American Society of Hematology meeting on November 4, 2026.Moves Vertex Pharmaceuticals
-
Royal Bank of Canada OperationalRoyal Bank of Canada boosted its stake in the S&P ETF on October 31, 2026.Moves Vertex Pharmaceuticals
-
FDA StructuralFDA approved a drug based on UVA research led by Xuemei Huang.Moves Vertex Pharmaceuticals
-
Bank of America TransactionalFinancial firms, including Scotiabank, Bank of America, Morgan Stanley, and Jefferies, provided rating and price target updates for DT Midstream, Inc.Moves Vertex Pharmaceuticals
-
Securities and Exchange Commission StructuralRegion faces fraudulent investment schemes, with the SEC having a zonal director in Port Harcourt.Moves Vertex Pharmaceuticals
-
Morgan Stanley OperationalMorgan Stanley raised its stock price target for Disney+ on November 10, 2026.Moves Vertex Pharmaceuticals
Connections
The 40 strongest of 194, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
CRISPR Therapeutics Structural
CRISPR and Vertex maintain a strategic partnership for the joint development, commercialization, and shared profitability of the gene therapy Casgevy.
-
Crinetics Pharmaceuticals Structural
Vertex Pharmaceuticals acquired Crinetics Pharmaceuticals in a $10 billion deal, establishing a parent-subsidiary relationship.
-
Reshma Kewalramani Structural
Reshma Kewalramani serves as the CEO and President, leading the strategic direction of Vertex Pharmaceuticals.
-
Morgan Stanley Operational
Morgan Stanley provides ongoing financial advisory, ratings, and coverage services to Vertex Pharmaceuticals, including facilitating acquisition financing.
-
Royal Bank of Canada Operational
RBC provides financial ratings and price target recommendations that influence the market perception and stock performance of Vertex Pharmaceuticals.
-
Duncan McKechnie Structural
Duncan McKechnie serves as an executive, EVP, at Vertex Pharmaceuticals.
-
FDA Structural
FDA formally regulates Vertex Pharmaceuticals through drug approvals, designations, and scope limitations on treatments.
-
Bank of America Transactional
Bank of America provided analyst coverage and bridge financing for Vertex Pharmaceuticals' acquisition.
Show all 40 connections
-
Goldman Sachs Mentioned together
Goldman Sachs provides consistent financial analysis, stock picks, and buy ratings for Vertex Pharmaceuticals.
-
SPDR Structural
SPDR ETF holds a significant stake in Vertex Pharmaceuticals as part of its managed portfolio.
-
SEC Structural
Vertex Pharmaceuticals is subject to SEC oversight regarding institutional holdings and required regulatory filings.
-
Moderna Operational
Both companies are active peers in the competitive therapeutics segment, focusing on advanced treatments like AI in Synthetic Biology.
-
Amgen Operational
Vertex and Amgen are direct competitors in the biopharmaceutical market, frequently compared by investors and analysts.
-
Securities and Exchange Commission Structural
Vertex Pharmaceuticals is subject to formal regulatory oversight by the SEC, requiring specific stock ownership filings (13F).
-
Denmark Operational
Vertex Pharmaceuticals gains market access in Denmark through formal reimbursement agreements.
-
TD Cowen Mentioned together
TD Cowen provides financial analysis and price target coverage for Vertex Pharmaceuticals.
-
Invesco Structural
Invesco holds a large financial position in Vertex Pharmaceuticals.
-
Norges Bank Transactional
Norges Bank acquired a new position in Vertex Pharmaceuticals shares.
-
England Operational
Vertex Pharmaceuticals' medicine is covered by the National Health Service in England via a formal reimbursement agreement.
-
Halozyme Therapeutics Structural
The relationship is characterized by a formal partnership structure where one entity operates as a subsidiary regarding Hypercon technology.
-
Cystic Fibrosis Foundation Operational
Vertex Pharmaceuticals develops treatments that actively support the mission and focus area of the Cystic Fibrosis Foundation.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides investment ratings and target price analysis for Vertex Pharmaceuticals.
-
Leerink partners Mentioned together
Leerink Partners provides market coverage and sets price targets for Vertex Pharmaceuticals shares.
-
Citigroup Operational
Citigroup publicly upgraded its investment recommendation regarding Vertex Pharmaceuticals, influencing market perception.
-
National Institutes of Health Transactional
NIH provided funding to Vertex Pharmaceuticals for pivotal research in drug development.
-
UBS Mentioned together
UBS provided a buy rating and raised the target price for Vertex Pharmaceuticals.
-
Biogen Operational
Vertex Pharmaceuticals and Biogen are direct competitors, both developing and marketing therapies for serious diseases.
-
SpaceX Operational
The relationship is characterized by active competition, with Vertex Pharmaceuticals noted to possess greater market dominance than SpaceX.
-
AbbVie Operational
AbbVie and Vertex Pharmaceuticals are engaged in direct market and legal competition.
-
RBC Capital Markets Transactional
Analyst commentary focuses on the acquisition premium between the two companies.
-
Biotech Shared context
Vertex Pharmaceuticals is identified as a major holding within the broader biotech sector ETF.
-
Truist Financial Mentioned together
Truist Financial provides market research coverage, including target price boosts and rating changes, for Vertex Pharmaceuticals.
-
Danaher Corporation Mentioned together
Both companies are identified as major players within the biotech sector.
-
Scotiabank Mentioned together
Scotiabank provides financial analysis and price targets for Vertex Pharmaceuticals.
-
Nvidia Mentioned together
The entities are co-mentioned in market analysis as high-growth stocks.
-
Benzinga Mentioned together
Benzinga reports and tracks Vertex Pharmaceuticals' financial performance and price targets.
-
Gilead Sciences Operational
Both companies are identified as major competitors operating in the biotechnology sector.
-
Leiden Shared context
Vertex Pharmaceuticals is contextually linked to Leiden via the historical role of a former CEO.
-
MarketBeat Mentioned together
MarketBeat features Vertex Pharmaceuticals in its stock screener and provides consensus rating data.
-
FogPharma Mentioned together
The companies are co-mentioned as entities involved in the drug development industry.
History
Events by the month they beganNovember 2026
6 events- Multiple financial firms, including Americana Partners and Summit Global Investments, adjusted their holdings in Vertex Pharmaceuticals on November 4, 2026.
- Royal Bank of Canada raised its price objective for Vertex Pharmaceuticals, with Benzinga and MarketBeat reporting related analyst changes.
- Vertex Pharmaceuticals added PALSONIFY as its fourth pillar in a recent acquisition.
- CRISPR Therapeutics and Vertex Pharmaceuticals split profits and costs for Casgevy, while CRISPR plans to present pipeline data at the AHA meeting.
- Sumitomo Mitsui Trust Holdings and Daiwa Securities Group announced changes to their holdings and ratings for Vertex Pharmaceuticals stock.
- Mirae Asset Global Investments Co. Ltd. purchased shares of Vertex Pharmaceuticals.
October 2026
2 eventsSeptember 2026
5 events- Both Vertex Pharmaceuticals and The Pennant Group operate within the healthcare sector.
- Vertex Pharmaceuticals CEO leads the company's strategic business direction.
- Vertex Pharmaceuticals presented updates at a Wells Fargo conference on September 12, 2026.
- Vertex Pharmaceuticals had required 13F filings with the SEC and its stock traded on the Nasdaq exchange on September 8, 2026.
- Goldman Sachs updated its top stock picks, removing Interactive Brokers and adding Vertex Pharmaceuticals.
Show 3 earlier months
August 2026
11 events- Vertex Pharmaceuticals trades on Nasdaq, files reports with the SEC, and has an executive named Duncan McKechnie.
- Direct financial comparison of two market rivals: Vertex Pharmaceuticals and Prothena Corporation plc.
- AbbVie previously failed challenges against Vertex Pharmaceuticals in the context of Cystic Fibrosis (CF).
- Norges Bank acquired a new position in the shares of Vertex Pharmaceuticals.
- Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.
- Siona's trial failure allowed Vertex dominance to surge.
- FogPharma and Vertex Pharmaceuticals are involved in drug development.
- Vertex Pharmaceuticals filed documents with the SEC detailing institutional investment oversight.
- Vertex acquired Crinetics Pharmaceuticals, while Neurocrine Biosciences acquired Soleno Therapeutics.
- Vertex Pharmaceuticals and Truist Financial disclosed insider trading transactions to the SEC.
- MarketBeat listed Vertex, Alnylam, Regeneron, Amgen, Danaher, TG Therapeutics, and Gilead Sciences as stocks to watch.
July 2026
8 events- The competitive landscape is shifting as Amazon's Leo challenges Starlink's business, while Vertex Pharmaceuticals demonstrates market dominance over SpaceX.
- Vertex Pharmaceuticals and Entera Bio were compared based on their market metrics.
- Leerink Partners advised Crinetics during the acquisition process, while analyst commentary scrutinized the acquisition premium.
- Various ETFs, including Invesco and VanEck, are reported to hold significant positions in major biotech and pharmaceutical companies.
- Moderna and Vertex Pharmaceuticals are now holdings in the GNOM ETF.
- Vertex Pharmaceuticals announced it has agreed to acquire Crinetics Pharmaceuticals.
- Market activity on July 7, 2026 includes Deutsche Bank upgrading First Solar stock, the acquisition of Crinetics by Vertex Pharmaceuticals, and market selloffs affecting chip stocks and Korea.
- Vertex Pharmaceuticals stock gains far exceeded S&P 500 returns on July 6, 2026.
June 2026
28 events- CRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.
- CRISPR Therapeutics formed a strategic partnership with Vertex Pharmaceuticals.
- Morgan Stanley began research coverage on Vertex Pharmaceuticals, raising its target price and giving it an overweight rating, alongside institutional filings.
- Vertex Pharmaceuticals lost market share due to illegal knockoffs of its medicines.
- Ono Pharmaceutical and Vertex Pharmaceuticals signed an exclusive collaboration for Povetacicept in Japan and South Korea.
- The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
- CRISPR Therapeutics and Vertex Pharmaceuticals successfully developed Casgevy in collaboration as part of their strategic partnership.
- MarketBeat featured Danaher, Moderna, and Vertex Pharmaceuticals in its stock screener.
- Goldman Sachs named Vertex Pharmaceuticals a top healthcare stock pick on July 15, 2025.
- Vertex Pharmaceuticals stock price objective was boosted, triggering a requirement for 13F filings regarding stock ownership.
- Carmen Bozic, CMO of Vertex Pharmaceuticals, sold company stock on June 23, 2026.
- CRISPR and Vertex Pharmaceuticals developed the CASGEVY therapy, noting growing treatment centers in Europe and the US.
- Benzinga reported on the financial performance of Vertex Pharmaceuticals.
- Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.
- The FDA is involved as Merck starts trials for a cystic fibrosis medicine developed with Vertex, leading to drug access agreements in Denmark and Ireland.
- EPAM Systems, Paramount Global, and Vertex Pharmaceuticals were identified as major high-growth stocks.
- Vertex Pharmaceuticals is mentioned in a Loomis Sayles letter regarding Trump-era tariffs and onshoring trends.
- Vertex Pharmaceuticals presented clinical data at the American Diabetes Association conference held in Chicago on June 25, 2025.
- PGIM Jennison Health Sciences Fund held Vertex Pharmaceuticals in its portfolio in July 2025.
- Vertex Pharmaceuticals' performance is linked to broader market movements, supported by new reimbursement agreements in Ireland and Denmark.
- A reimbursement deal for the drug ALYFTREK has been reached between Vertex Pharmaceuticals and NHS England.
- Vertex Pharmaceuticals and Inspire Medical Systems both reported positive Earnings Stock Purchase Plan (ESP) figures.
- Vertex Pharmaceuticals, based in Boston, launched JOURNAVX, a new medication offering a safer alternative to opioids.
- FDA approved Journavx for pain treatment on August 1, 2025.
- Vertex Pharmaceuticals was removed from Russell indexes on August 7, 2025.
- Buying opportunities emerged for Costco, Netflix, ASML Holding, and Vertex Pharmaceuticals following a market pullback on August 8, 2025.
- The Buffett Indicator reached a record high, involving Vertex Pharmaceuticals.
- FDA feedback limited the initial scope of suzetrigine, leading to Goldman Sachs analysts questioning the drug's label loss.